ArticleFolia microbiologica2026
Bacillus atrophaeus as a high-performance microbial nanofactory for monodisperse selenium nanoparticles with exceptional antifungal potency, antioxidant capacity, anticancer activity, and validated molecular docking interactions.
Article in Folia microbiologica, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Biogenic selenium nanoparticles are a promising new branch of functional nanomaterials with attractive antimicrobial activity, antioxidant properties, and anticancer properties but their complete integrated characterization between synthesis, structure, molecular pathway, and safety has not fully been investigated. A rhizosphere Bacillus atrophaeus isolate was used in this research as an effective microbial nanofactory to produce highly uniform extracellular selenium nanoparticles. The resulting particles had a Z-average diameter of 126.4 ± 0.5 nm, a small polydispersity index of 0.145 and a stable negative surface charge of -32.5 mV. Biomolecular capping, amorphous structure, and spherical morphology were confirmed by physicochemical methods including UV-vis spectroscopy, TEM, SEM, XRD, and FTIR. The nanoparticles exhibited effective broad-spectrum antimicrobial effects with 16.5–24.2 mm bacterial and 22.0–39.3 mm fungal inhibition areas, and Aspergillus ochraceus was the most susceptible to the nanoparticles (39.3 mm). Assessment of antioxidants demonstrated a high radical scavenging ability with the IC50 equals 41.92 µg/mL, anticancer evaluation against HepG2 cells displayed dose-dependent cytotoxicity with the IC50 equals 94.71 µg/mL and also up to 77% cell viability reduction at a 200 µg/mL concentration. Molecular docking revealed that it interacts well with catalytic regions of bacterial DNA gyrase and fungal RNA polymerase in view of the antimicrobial mechanism observed. A positive forecast of safety margin, with no organ-level, mutagenic, carcinogenic, immunotoxic, and metabolic toxicity was predicted by in silico toxicity profiling. Taken altogether, the analysis of these results confirms that B. atrophaeus is a promising microbial system to be used in sustainable manufacturing of versatile selenium nanoparticles with an enormous therapeutic and biotechnological potential.
Indexed as
Identifiers
41979816What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.